Alnylam Pharmaceuticals, Inc. (ALNY) announced positive interim results from an ongoing phase I study, evaluating its pipeline candidate, ALN-AS1.
BioMarin Pharmaceutical (BMRN) reported a narrower-than-expected second-quarter 2016 loss of 11 cents per shares; revenues beat estimates while the view was upped.
Sanofi (SNY) reported second-quarter 2016 business earnings of 74 cents per American Depositary Share, in line with the Zacks Consensus Estimate.
Sanofi's (SNY) begins dosing of the first adult patient in a phase II/III study on olipudase alfa; Praluent gains approval in Japan.
Ionis Pharmaceuticals (IONS) reported a wider-than-expected first-quarter 2016 loss of 52 cents; revenues plunged year over year.
Alnylam (ALNY) reported a loss of $1.21 per share in the first quarter of 2016 on revenues of $7.3 million.
BioMarin (BMRN) reported a loss of 35 cents per share in the first quarter of 2016, narrower than the Zacks Consensus Estimates of a loss of 85 cents.
PARIS (Reuters) - Sanofi and its takeover target Medivation dug in for trench warfare on Friday, with the French drugmaker confident of winning over investors and the U.S. cancer firm insisting it was better off staying independent.
ПРООН заключила контракты с пятью компаниями на поставку препаратов от детской гемофилии на $6,955 млн
Программа развития ООН (UNDP) заключила контракты с пятью компаниями на поставку 15-ти препаратов для лечения детской гемофилии на $6,955 млн (с учетом логистики).
Bayer's (BAYRY) hemophilia drug, Kovaltry, was approved in the U.S. for the treatment of children and adults with hemophilia A.
Alnylam Pharmaceuticals (ALNY) announced that it has initiated a phase I/II study on ALN-GO1 for the treatment of primary hyperoxaluria type 1.
Sanofi (SNY) and its specialty care global business unit, Genzyme, presented data from a phase I/II study on late-onset Pompe disease candidate neoGAA.
Alnylam (ALNY) reported a loss of $1.07 per share in the fourth quarter of 2015 on revenues of $7.6 million.
Sanofi (SNY) reported fourth-quarter 2015 business earnings of 72 cents per American Depositary Share, beating the Zacks Consensus Estimate of 69 cents.
Alnylam (ALNY) filed a CTA for ALN-GO1 with the UK Medicines and Healthcare products Regulatory Agency for the treatment of primary hyperoxaluria type 1.
Alnylam (ALNY) announced the initiation of the final phase of the phase I/II study on ALN-CC5 for the treatment of patients with complement-mediated diseases.
Alnylam (ALNY) reported a loss of 91 cents per share in the third quarter of 2015 on revenues of $6.3 million.